Live Breaking News & Updates on Blais University Chair
Stay updated with breaking news from Blais university chair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, announces an. ....
Katherine Fitzgerald and Nikolaus Grigorieff elected to National Academy of Sciences Record number of women elected to academy in 2021 By Colleen Locke April 27, 2021 The private, nonprofit society of distinguished scholars is charged with providing independent, objective advice to the nation on matters related to science and technology. The Academy elected 120 new members on April 26, including a record 59 women and 30 international members. Katherine Fitzgerald, PhD “I am delighted to be elected to the NAS and to have my lab’s work recognized with this incredible honor,” said Dr. Fitzgerald, the Worcester Foundation for Biomedical Research Chair, professor of medicine and director of the Program in Innate Immunity. ....
Caresyntax and UMass Medical School Program on Surgical Safety Selected for 2020 Massachusetts Digital Health Sandbox Network Will identify predictive indicators of surgical risk, develop simulation programs to remotely train residents News provided by Share this article Share this article BOSTON, Jan. 19, 2021 /PRNewswire/ Caresyntax, a pioneer in surgical automation, analytics, and AI software and technologies, today announced that it was selected to join the Massachusetts Digital Health Sandbox Network as part of a joint project with the University of Massachusetts Medical School (UMMS) to install a digital platform in operating rooms that can enable video-based assessments of a surgeon s technical performance. ....
Atalanta Therapeutics founded by UMass Medical School and three faculty members Biotech launches with $110 million to pioneer RNA therapeutics for neurodegenerative diseases By Mark L. Shelton January 12, 2021 Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech. Atalanta’s technology, called branched siRNA and licensed from UMass Medical School, is based on more than 30 years of research at the Medical School in the field of RNA biology and its clinical applications. Branched siRNA is a novel oligonucleotide architecture that has shown potent ability to silence gene expression in the central nervous system and can be applied across multiple neurodegenerative diseases. ....